Denmark | Finland | Iceland | Norway | Sweden | ||||||
Treatment cohorts | Etanercept | oTNFi | Etanercept | oTNFi | Etanercept | oTNFi | Etanercept | oTNFi | Etanercept | oTNFi |
Episodes, n | 3175 | 9208 | 1244 | 2739 | 366 | 1231 | 1018 | 2731 | 8581 | 16 279 |
Patients*, n | 2896 | 6140 | 946 | 1928 | 144 | 818 | 713 | 1980 | 5440 | 9803 |
TNFi | ||||||||||
Adalimumab | 0 | 3552 | 0 | 1341 | 0 | 367 | 0 | 617 | 0 | 7114 |
Certolizumab pegol | 0 | 924 | 0 | 175 | 0 | <5 | 0 | 870 | 0 | 1291 |
Infliximab | 0 | 3280 | 0 | 661 | 0 | 717 | 0 | 576 | 0 | 5261 |
Golimumab | 0 | 1452 | 0 | 562 | 0 | 145 | 0 | 668 | 0 | 2613 |
Female (%) | 1632 (51) | 4303 (47) | 559 (45) | 1143 (42) | 216 (59) | 616 (50) | 506 (50) | 1387 (51) | 4431 (52) | 7844 (48) |
Age at TNFi start | 45 (35–54) | 43 (34–53) | 44 (34–54) | 45 (35–53) | 47 (37–55) | 45 (35–55) | 43 (34–53) | 44 (36–54) | 47 (36–57) | 45 (35–55) |
Disease duration (years) | ||||||||||
<1 | 349 (12) | 1384 (16) | 52 (5) | 153 (6) | 69 (21) | 345 (33) | 197 (26) | 397 (21) | 496 (6) | 867 (5) |
1–5 | 1293 (44) | 3407 (40) | 371 (33) | 810 (32) | 115 (35) | 296 (28) | 214 (29) | 520 (27) | 2069 (24) | 3745 (23) |
>5 | 1306 (44) | 3725 (44) | 700 (62) | 1531 (61) | 140 (43) | 410 (39) | 334 (45) | 979 (52) | 5937 (70) | 11 507 (71) |
Number of previous b/tsDMARDs | ||||||||||
0 | 1467 (46) | 5978 (65) | 885 (71) | 1820 (66) | 143 (39) | 817 (66) | 579 (57) | 1447 (53) | 5312 (62) | 9650 (59) |
1 | 1240 (39) | 1809 (20) | 311 (25) | 565 (21) | 175 (48) | 252 (20) | 301 (30) | 742 (27) | 2259 (26) | 3829 (24) |
2 | 351 (11) | 869 (9) | 36 (3) | 262 (10) | 35 (10) | 114 (9) | 101 (10) | 345 (13) | 655 (8) | 1765 (11) |
3 | 97 (3) | 394 (4) | 9 (1) | 74 (3) | 11 (3) | 38 (3) | 26 (3) | 137 (5) | 253 (3) | 743 (5) |
4 | 20 (1) | 158 (2) | 3 (0) | 18 (1) | 2 (1) | 10 (1) | 11 (1) | 60 (2) | 102 (1) | 292 (2) |
Clinical measurements | ||||||||||
CRP | 5.0 (2.0–14.3) | 6.0 (2.0–16.0) | 8.0 (3.0–20.0) | 7.0 (3.0–19.0) | 4.0 (2.0–10.0) | 6.0 (3.0–14.0) | 5.0 (2.0–11.0) | 5.0 (2.0–10.0) | 5.0 (2.0–14.0) | 6.0 (2.0–17.0) |
SJC | 0 (0–2) | 0 (0–2) | 1 (0–2) | 1 (0–2) | 2 (0–5) | 1 (0–4) | 0 (0–1) | 0 (0–1) | 1 (0–3) | 0 (0–3) |
TJC | 2 (0–7) | 2 (0–6) | 1 (0–3) | 1 (0–3) | 3 (0–6) | 2 (0–5) | 0 (0–3) | 1 (0–3) | 2 (0–6) | 2 (0–6) |
PGH | 28 (15–45) | 29 (15–45) | 51 (25–70) | 50 (25–70) | 70 (48–82) | 70 (50–83) | 57 (37–74) | 54 (35–72) | 62 (44–76) | 62 (43–77) |
HAQ† | 1.0 (0.6–1.5) | 1.0 (0.6–1.5) | 0.8 (0.3–1.4) | 0.8 (0.4–1.3) | 1.0 (0.6–1.5) | 0.9 (0.5–1.4) | 0.6 (0.3–0.9) | 0.6 (0.3–0.9) | 0.9 (0.5–1.3) | 0.9 (0.5–1.3) |
Pain VAS | 66 (46–81) | 66 (47–80) | 55 (30–71) | 55 (30–72) | 66 (44–80) | 67 (47–79) | 53 (32–71) | 51 (31–70) | 63 (44–76) | 63 (43–77) |
BASDAI | 6.4 (4.8–7.7) | 6.3 (4.8–7.7) | 4.1 (1.8–6.2) | 4.2 (2.0–5.9) | 6.5 (5.8–8.1) | 6.1 (4.5–7.6) | 5.3 (3.4–6.8) | 5.0 (3.2–6.6) | 5.8 (4.1–7.1) | 5.8 (4.1–7.2) |
ASDAS | 3.5 (2.8–4.1) | 3.4 (2.7–4.1) | 2.9 (2.1–3.7) | 2.8 (1.9–3.5) | 3.3 (2.7–4.2) | 3.5 (2.9–4.0) | 2.9 (2.3–3.7) | 2.9 (2.2–3.6) | 3.1 (2.4–3.8) | 3.2 (2.4–3.8) |
Concomitant methotrexate | 979 (31) | 3042 (30) | 369 (44) | 949 (52) | 92 (25) | 292 (24) | 228 (22) | 734 (27) | 3266 (38) | 6805 (42) |
Comorbidities | ||||||||||
IBD | 102 (3) | 487 (5) | 21 (2) | 164 (6) | 4 (1) | 35 (3) | 15 (1) | 164 (6) | 235 (3) | 1420 (9) |
Diabetes | 53 (2) | 128 (1) | 9 (1) | 15 (1) | 2 (1) | 9 (1) | 13 (1) | 37 (1) | 124 (1) | 225 (1) |
Thyroidea | 113 (4) | 243 (3) | 17 (1) | 30 (1) | 1 (0) | 6 (0) | 12 (1) | 49 (2) | 238 (3) | 365 (2) |
Smoking | ||||||||||
Current | 349 (11) | 906 (10) | 25 (2) | 100 (4) | 57 (16) | 184 (15) | 196 (19) | 501 (18) | 571 (7) | 1164 (7) |
Former | 240 (8) | 495 (5) | 8 (1) | 33 (1) | 86 (23) | 198 (16) | 286 (28) | 774 (28) | 1719 (20) | 3241 (20) |
Never | 492 (16) | 1249 (14) | 105 (8) | 348 (13) | 129 (35) | 426 (35) | 361 (35) | 931 (34) | 2096 (24) | 3957 (24) |
Missing | 2094 (66) | 6558 (71) | 1106 (89) | 2258 (82) | 94 (26) | 423 (34) | 175 (17) | 525 (19) | 4195 (49) | 7917 (49) |
Median (quartiles, IQR) for continuous variables and number (percentages) for binary variables are displayed. If not otherwise specified, the statistics pertain to treatment episodes. All variables are measured at treatment start.
*Patients were allowed starting a treatment with the same molecule several times.
†mHAQ in Norway.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; b/tsDMARD, biologic or targeted synthetic disease-modifying antirheumatic drug; CRP, C reactive protein (mg/L); HAQ, Health Assessment Questionnaire; IBD, inflammatory bowel disease; mHAQ, modified Health Assessment Questionnaire; oTNFi, other tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, infliximab, golimumab); PGH, patient’s global health assessment; SJC, 28 swollen joint count; SpA, spondyloarthritis (including psoriatic arthritis and ankylosing spondylitis); TJC, 28 tender joint count; TNFi, tumour necrosis factor inhibitor; VAS, 0–100 Visual Analogue Scale.